Collegium Pharmaceutical (COLL) Raw Materials (2016 - 2025)

Collegium Pharmaceutical's Raw Materials history runs 10 years deep, the most recent figure standing at $8.3 million for Q3 2025.

• On a quarterly basis, Raw Materials rose 98.31% year-over-year to $8.3 million in Q3 2025; TTM through Sep 2025 was $8.3 million, a 98.31% increase from a year earlier, with the FY2024 full-year figure at $12.5 million, up 20.68% from the prior year.
• Raw Materials slipped to $8.3 million in Q3 2025 per COLL's latest filing, from $9.5 million in the prior quarter.
• Across five years, Raw Materials topped out at $14.4 million in Q3 2023 and bottomed at $3.7 million in Q4 2021.
• The 5-year median for Raw Materials is $7.2 million (2024), against an average of $7.7 million.
• Across the five-year window, Raw Materials surged 149.84% in 2023 and slumped 70.8% in 2024, its largest moves.
• Year by year, Raw Materials stood at $3.7 million in 2021, then surged by 51.97% to $5.6 million in 2022, then jumped by 85.43% to $10.4 million in 2023, then advanced by 20.68% to $12.5 million in 2024, then plunged by 33.48% to $8.3 million in 2025.
• Per Business Quant, the three latest COLL Raw Materials figures stand at $8.3 million (Q3 2025), $9.5 million (Q2 2025), and $11.8 million (Q1 2025).